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Abstract
Background: Breast cancer incidence and mortality vary significantly among different nations and racial groups. African
nations have the highest breast cancer mortality rates in the world, even though the incidence rates are below those of
many nations. Differences in disease progression suggest that aggressive breast tumors may harbor a unique molecular
signature to promote disease progression. However, few studies have investigated the pathology and clinical markers
expressed in breast tissue from regional African patient populations.
Methods: We collected 68 malignant and 89 non-cancerous samples from Kenyan breast tissue. To characterize the
tumors from these patients, we constructed tissue microarrays (TMAs) from these tissues. Sections from these TMAs
were stained and analyzed using immunohistochemistry to detect clinical breast cancer markers, including estrogen
receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) status, Ki67, and immune
cell markers.
Results: Thirty-three percent of the tumors were triple negative (ER-, PR-, HER2-), 59 % were ER+, and almost all tumors
analyzed were HER2-. Seven percent of the breast cancer patients were male, and 30 % were <40 years old at diagnosis.
Cancer tissue had increased immune cell infiltration with recruitment of CD163+ (M2 macrophage), CD25+ (regulatory
T lymphocyte), and CD4+ (T helper) cells compared to non-cancer tissue.
Conclusions: We identified clinical biomarkers that may assist in identifying therapy strategies for breast cancer
patients in western Kenya. Estrogen receptor status in particular should lead initial treatment strategies in these
breast cancer patients. Increased CD25 expression suggests a need for additional treatment strategies designed to
overcome immune suppression by CD25+ cells in order to promote the antitumor activity of CD8+ cytotoxic T cells.
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Background
Breast cancer is the most frequently diagnosed and the
most deadly cancer among women worldwide, taking
roughly half a million lives per year [1]. Between 1980 and
2010, the global rate of breast cancer incidence increased
2.6 times (i.e., from 641,000 to 1,643,000 patients) [2].
Unfortunately, the global rates of breast cancer inci-
dence and mortality continue to increase, particularly
in developing countries [2]. In fact, 59 % of the world-
wide breast cancer deaths is estimated to occur in de-
veloping countries [1].
Similar to global cancer trends, breast cancer is the most
highly diagnosed and leading cause of cancer deaths in
women throughout Africa (63,100 deaths in 2012) [3].
However, in Africa, noncommunicable diseases like cancer
are not considered as pressing of a burden to society as
infectious diseases, which have a higher prevalence in the
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patient population. Limited resources for surveillance,
treatment, and research, as well as low public awareness
campaigns for early detection and treatment affect the rate
of cancer diagnosis. In addition, most standard care and
treatments used globally for treating breast cancer are
derived from research on patient populations in resource-
rich developed countries, which results in challenging im-
plementation strategies in resource-poor countries [4, 5].
Even within developed countries, breast cancer disease
etiology and progression can be quite heterogeneous
across patient populations. In contrast to global increases
in breast cancer incidence and mortality, the U.S. breast
cancer mortality declined as much as 34 % since 1990
[6, 7]. This decline is not consistent across patient
groups and varies significantly by race/ethnicity. Non-
Hispanic white women have the highest incidence of
breast cancer, while African American women have
both the highest mortality rate (30.8 deaths per 100,000
females) compared to non-Hispanic white females (22.7
deaths per 100,000) as well as the lowest 5-year cause-
specific survival (78.9 %) compared to non-Hispanic
whites (88.6 %).
Contributing to the differences in mortality rates, African
American women in the U.S. develop breast cancer with a
higher grade and a higher representation of early-onset,
high-grade, node-positive, and hormone receptor-negative
tumors than do patients of other races [8]. A decreased
five-year survival rate for African Americans is associated
with the pathological presentation at diagnosis but not
with patient age or treatment differences [9]. Across age
groups, African American women commonly develop
tumors that are diagnosed beyond stage I, and African
American women who present with stage I disease also
have a higher death rate than matched white women [10].
While the striking racial differences in mortality are
due in part to differential access to health care for both
early detection and treatment of disease, these statistics
also reflect the differential incidence of molecular sub-
types of breast cancer with poor prognosis across patient
populations. Underlying genetic differences across pa-
tient populations may harbor unique molecular signa-
tures that result in racial disparities in prognosis and
response to treatment. For example, estrogen receptor
(ER) status is differentially expressed across racially di-
verse patient populations. In the U.S., even though African
Americans and Hispanics have a higher incidence of ER-
breast cancer than is seen in non-Hispanic whites, the
majority of African American breast tumors are ER+ [11].
In contrast, tumors from Africa have more heterogeneity.
Tumors from breast cancer patients in Nigeria and
Senegal were predominantly ER- [12–14], while tumors
from another group of patients in Nigeria were predomin-
antly ER+ [15]. Identification of additional molecular
markers of breast cancer will help us to understand
regional differences that are relevant to disease etiology
and treatment.
Of African countries, Kenya has among the highest
risk of breast cancer [3]. Breast cancer incidence and
mortality rates also have increased significantly since
1980 rates [3]. The goal of our research is to begin to
identify underlying molecular mechanisms that promote
Kenyan breast cancer by comparing our patient popula-
tion to patients from Kenya, other parts of East Africa,
and African Americans. In this study, we identify the
expression patterns of clinical markers in a western
Kenyan patient population not studied previously. For
this analysis, we selected a patient population from the
Moi Teaching and Referral Hospital patient population
because previous Kenyan studies looking at the clinical
markers of breast cancer were completed in Nairobi,
which is a larger metropolis and has different ethnic
group demographics, environmental variables, and ethnic
groups than the regional areas of Eldoret. A better
characterization of the regional differences in breast
cancer will guide the creation of early detection programs
and effective treatment strategies designed to reduce the
cancer mortality rates and suffering in both African and
related patient populations.
Methods
Patient samples and geographic region
These studies follow appropriate ethical standards and
are in accordance with and have been approved by IRBs
from both the University of Notre Dame (IRB Approval
# 13-06-1102) and Moi University (IRB Approval #
000655). The tissue samples were collected with patient
consent at Moi Teaching and Referral Hospital (MTRH),
which is the primary academic hospital that serves the
entire western Kenya community and is located in the
city of Eldoret town (population: 289,380), Uasin Gishu
district, North of Rift Valley province of Kenya. Uasin
Gishu County is home to 894,179 people. Therefore, the
the catchment area for MTRH is a fairly large community
and represents a large population. Eldoret is surrounded by
agricultural regions and is 330 km northwest of Nairobi.
The significant distance between Eldoret and Nairobi
makes MTRH a highly utilized hospital facility. As a re-
gional hospital, MTRH treats patients not only from west-
ern Kenya but also from eastern Uganda and southern
Sudan. Accruing patient samples from one hospital is com-
mon in related population-focused studies (e.g., [16–19]).
Study design
This was a prospective study in which samples were
collected consecutively. All breast cancer patients who
consented to participation in this study and who
attended the MTRH oncology clinic between May 2011
and July 2013 were included in this study (Table 1). The
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patients included in this study were included in this
study after informed consent and had either nonmalig-
nant lumps or clinically established breast cancer (both
women and men). The patients had no history of other
cancers and no history of chemotherapy prior to diagno-
sis. The patients who were excluded from the study
included patients who did not provide consent, those
with a history of other cancer, and those who had a his-
tory of treatment with chemotherapy. Using non-cancer
tissue from the control population was an important
control for the immune cell analysis to provide a base-
line comparison of our analysis of the immune cells in
cancer tissue to normal tissue in Kenyan breast tissue. In
Kenya, breast reduction surgery for cosmetic reasons is
uncommon, making it difficult to get true normal tissue.
Benign tissues with a normal pathology are typical con-
trols in immune cell quantification analysis when estab-
lishing differences in cell populations between cancer vs.
not cancer samples [20, 21].
Each patient also volunteered clinical data, including a
family history of breast cancer or related cancers, saliva
was collected, and tumors were obtained from surgical
procedures, including mastectomies. Secondary data in-
cluding HIV status and other medical conditions were
extracted from the patients’ files. Incomplete clinical
data for the patients was assembled for the patients
included in this study. Clinical data was collected from
both a questionnaire and from patient records. A ques-
tionnaire was administered to all patients who consented
to be a part of this study. This enabled collection of the
following information: demographic characterization,
name, age, gender, nationality, ethnic group, place of
birth, village location, county, marital status, weight,
and height. Patients also provided information on
disease status, when diagnosis was made, treatment,
tumor characteristics, left or right, axillary lymph nodes
palpability, family history, and risk factors that included
age at first menarche, number of pregnancies, breast
feeding, use of oral or injective contraceptives, use of
HRT, smoking, alcohol consumption, and other envir-
onmental factors.
Table 1 Clinical characteristics of Western Kenya patient
population
Cancer Not Cancer
N % N %
Cancer status
Cancer Tissue 68 100 0 0
Not Cancer Breast Tissue 0 0 89 87
Other Tissue 0 0 13 13
Total (N) 68 102
Gender
Male 4 7 6 8
Female 54 93 70 92
Total (N) 58 76
Age at diagnosis
<40 years 16 30 42 74
40-49 years 11 21 10 18
≥50 years 26 49 5 9
Total (N) 53 57
HER2 status
Positive 7 14
Negative 42 86
Total (N) 49
Estrogen receptor status
Positive 29 59
Negative 20 41
Total (N) 49
Progesterone receptor status
Positive 19 40
Negative 29 60
Total (N) 48
Triple negative (ER-, PR-,
HER2-)
16 33
Total (N) 48
Status
Died 11 69
Alive 5 31
Total (N) 16
Tribe
Luyha 11 38
Kalenjin 10 34
Kikuyu 4 14
Luo 3 10
Teso 1 3
Total (N) 29
Hormone-based Contraception
Single agent (Injected or Pill) 11 50
Combined (Injected and Pill) 2 9
Table 1 Clinical characteristics of Western Kenya patient
population (Continued)
Neither 9 41
Total (N) 22
Marriage
Married or widowed 24 92
Not Married 2 8
Total (N) 26
Median age (years) 48.5 years (N = 38) 31 years old (N = 9)
Mean age (years) 51.9 years (N = 38) 35.6 years (N = 9)
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MTRH is the only hospital in western Kenya that
is in the AMPATH consoritum. AMPATH promotes
care, training, and research as part of its mission
and allows “Kenyan leaders to draw upon the re-
sources and talents of North American academic
health institutions to tackle the challenges of
disease and poverty” (AMPATH website). By being
part of the AMPATH consortium, these Kenyan in-
stitutions have received extensive training and
equipment from these universities. The AMPATH
consortium is led by Indiana University and in-
cludes multiple universities and academic medical
centers in North America.
Tissue fixation and processing
Harvested specimens were fixed in 10 % neutral buffered
formalin, then routinely processed in a Leica TP 1020
tissue processor (Leica Microsystems Inc., Nussloch
Gmbh Heidelbeger Nussloch Germany), and paraffin
embedded in Paraplast X-tra (McCormick™ Scientific).
The embedded tissue blocks were transferred from the
MTRH hospital to the University of Notre Dame and
submitted for further studies following IRB approval
from both institutions. The Kenyan tissue samples
were subsequently melted down and re-embedded in
Surgipath EM_400 paraffin (Leica Biosystems Inc.),
using a Sakura Tissue TEK5 embedding station. Paraf-
fin sections for all studies were cut at 3–4 μm in
thickness on a Leica RM2125-RTS rotary microtome
for hematoxylin and eosin (H&E) and immunohisto-
chemical staining.
Pathology
The 3 μm cut tissue slides were stained with Hematoxylin
& Eosin (Richard Allan Scientific; Kalamazoo, MI) and
submitted for blinded microscopic examinations by a
U.S. board certified breast pathologist (S.B.), a Kenyan
pathologist (D.C.), and a Ph.D. research pathologist
(Z.S.).
Tissue microarrays
Tissue microarrays (TMAs) were constructed from the
cancer and non-cancer breast tissue samples. Tissue
cores were punched from donor blocks with a 1 mm
diameter stylus and loaded to recipient blocks. Dis-
tance between tissue cores was also set at 1 mm. The
TMA layout on the recipient TMA blocks was prede-
signed to represent and distribute randomly across the
TMA blocks, the patient heterogeneity (i.e., cancer and
non-cancer) as identified by pathology. The specific re-
gions of the blocked tissues selected for the TMA cores
were based on the pathology diagnoses from the H&E
stained slides. The regions of interest for each block
was marked by a pathologist as guidance for core
extraction. TMA blocks were constructed with Veri-
diam Advanced Tissue Arrayer VTA-110CC. Each of
the two TMA constructed blocks used for the staining
had ~100 tissues per block with duplicates across the
two TMA blocks. A representative group of 92 tissue
samples were included on both of the constructed
TMA blocks.
Staining by immunohistochemistry (IHC)
The TMA blocks were sectioned onto Flex IHC slides
(Dako, Inc.), deparaffinized and hydrated, followed by
antigen retrieval in the PT Linker (Dako, Inc.). The
slides were stained for the indicated antibody and anti-
gen retrieval conditions summarized in Additional
file 1: Table S1. The IHC staining was processed on
a Dako Cytomation Autostainer Plus. And followed
with a Hematoxylin nuclear counterstain (Dako, Inc.). For
quality control purposes, known positive control and
negative control specimens were included for each anti-
body set.
Image scanning and analysis
The slides were digitally scanned at a 200X magnifica-
tion on an Aperio ScanScope CS whole slide scanner
(Leica, Biosystems, Inc.). The generated digital images
were saved onto the eSlide Manager database (ver.
12.0.1.5027).
To quantify the area of positive staining and
density or the number of cells stained with DAB
chromagen, customized macros for each stain were
generated from the Color Deconvolution and Cell
Quantification algorithms in the Aperio Image Ana-
lysis Tools software. All the cores and regions of
interest on each TMA slide were labelled and sub-
mitted for analysis with a proper validated macro for
each stain. The output results, included percentage
of positively stained area and density or positive
stained cell numbers of each intensity levels, respect-
ively. The mark up core images were re-evaluated,
and the generated data were exported from Image-
Scope annotation files as an Excel file for statistical
analyses. The scored regions of each sample were
checked manually to see if the algorithms had false
positives or false negatives. The sample was not in-
cluded if >10 % of the cells were misclassified.
Statistical analysis
Cancer and non-cancer (“not cancer”) samples were
compared by Mann-Whitney nonparametric analysis
using Prism software. All the tests used a confidence
interval of 95 % (α = 0.05).
To compare the ER status in our data and in METABRIC
data [22] while taking age into account, we used the
following logistic regression model:
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logitðπERÞ ¼ β0 þ β1⋅ageþ β2⋅Iðour data or notÞ
In the model, πER is the probability of ER-, age is the
age of the patient at diagnosis, and I(our data or not)
equals 1 if the patient is from our data, and 0 if the patient
is from the METABRIC data. Note that this model means
that for a patient in METABRIC data, logit(πER ‐) = β0 + β1
⋅ age, and for a patient in our data, logit(πER ‐) = β0 + β1 ⋅
age + β2. Therefore, to test whether the ER status is
different in the two datasets while taking age into
account, we tested H0: β2 = 0 vs HA: β2 ≠ 0. The p-value
was P = 0.11, which is not significant. This indicates that
the different ER- proportions in the two datasets is likely
caused by the age difference in the two populations. (Also,
our model confirms that age has a very significant effect on
ER status: β1 ≠ 0 with p-value < 1 × 10
−10.)
Results
Young age at diagnosis for breast cancer patients in
western Kenya
To characterize the breast cancer seen in western Kenya,
we first collected, processed, and sectioned 170 primary
breast tissue samples collected at the Moi Teaching and
Referral Hospital, Eldoret, Kenya (Fig. 1a). For an initial
pathological diagnosis based on morphological criteria,
we used hematoxylin and eosin (H&E) stained tissue
sections from each patient’s tumor tissue. From the
pathology analysis, we grouped the patient tissues into
cancer and not cancer categories. Based on this analysis,
we excluded patient samples that were not breast tissue,
were inconclusive, or were of low quality based on the
pathology. The remaining samples included 68 cancer
and 89 not cancer tumor tissue samples.
The Kenyan breast cancer patients who participated in
this study included a diverse group of patients ranging
from age 16 to 84 (Table 1). The median age at diagnosis
for the Kenyan breast cancer patient cohort was 48.5 years,
and the mean age was 51.9 years, which are both younger
than the mean age at diagnosis of U.S.-born white breast
cancer patients (64.1 years of age), U.S.-born black breast
cancer patients (59.1 years), or Jamaica-born black breast
cancer patients (56.5 years) who live in the U.S. [23]. This
mean age at diagnosis of this Kenyan cohort is similar in
age to both Western Africa-born black breast cancer
patients (48 years) and Eastern-Africa born black breast
cancer patients (48 years) who live in the U.S. [23].
Fifty-eight of the 68 patients with cancer provided
gender information. The breast cancer patients were
93 % female and 7 % male (i.e., 4 of 58 cancer patients).
The rate of male breast cancer is higher in this popula-
tion than the one percent rate seen in the U.S. [24] and
in other East African studies (Table 2) [17, 19, 25–29].
For additional analysis, we applied a Fisher’s exact test
to test whether our study has a larger proportion of male
breast cancer patient than is seen in other geographic
regions. The percentage of male breast cancer patients
was significantly different from other large breast cancer
population studies from Tunisia, Nigeria, and the United
States (N > 1437 patients) (Additional file 2: Table S2).
This suggests that the difference in percentage of male
patients is unlikely due to chance alone. We also com-
pared our patient population with smaller studies col-
lected in Kenya, Uganda, Tunisia, and Zimbabwe. While
the number of male breast cancer patients seen in our
Kenyan patient population did not reach statistical sig-
nificance, the lack of statistical significance in these
studies may be due to the smaller sample sizes.
Moreover, the patients predominantly come from two
ethnic groups (i.e., Luyha and Kelenjin), are married,
and have no known familial history of breast cancer.
More than half of the patients used either injected or pill
contraceptives.
Breast cancer pathologies are predominantly invasive
ductal carcinoma
We next examined the pathologies of the breast tissue
samples using H&E tissue sections from each tumor.
Invasive ductal carcinoma was the predominant pathology
seen in the malignant tumors (79 % of cancer tissues)
(Fig. 1b). Additional pathologies represented in the patient
population also included mucinous carcinoma, Paget’s dis-
ease, adenocarcinoma, invasive carcinoma, lobular carcin-
oma, invasive lobular carcinoma, papillary carcinoma,
invasive cribiform carcinoma, and undifferentiated carcin-
oma or sarcoma. Some of these tumors had significant in-
flammatory infiltration or mucinous pathologies associated
with the carcinoma (Fig. 1c).
The pathologies of the non-malignant tissues included
normal breast tissue as well as fibroadenoma and adeno-
sis, fibrocystic disease, ductal hyperplasia, atypical ductal
hyperplasia, apocrine metaplasia (not cancer), intraduc-
tal papilloma, papillary hyperplasia, tubular adenoma,
and lobular hyperplasia (Fig. 1b). Only one sample had
the pathology of ductal carcinoma in situ.
Kenyan breast cancer samples are HER2 negative and are
heterogeneous for ER and PR expression
We next scored and quantified the clinical markers
expressed in the breast tumor tissues collected for this
study. We analyzed the patient tissue samples for expres-
sion of clinical markers of breast cancer (e.g., HER2, estro-
gen receptor/ER, and progesterone receptor/PR) using
tissue microarrays (TMAs) we generated from the patient
breast tissue blocks. We first stained and scored TMA
sections for the receptor HER2 by immunohistochemistry
(Fig. 2a). Eighty-six percent of the cancer samples were
negative for HER2 expression. This distribution is similar
to that seen in the USA and western countries.
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We next stained TMA tissue sections by immunohis-
tochemistry for estrogen receptor (ER) and progester-
one receptor (PR) and scored the samples for positive
expression of these receptors in the epithelium (Fig. 2a
and Table 1). The majority of the cancers were ER posi-
tive (59 % ER positive vs. 41 % ER negative) and PR
negative (60 % PR negative vs. 40 % PR positive). These
rates are lower than those seen in western countries
but could be a reflection of the cancers occurring in
younger populations. To determine if the ER status was
expected based on the age of the population, we statis-
tically compared our dataset to another large breast
cancer patient dataset (analysis described in Methods)
(N = 1992 patients, METABRIC) [22]. Our analysis sug-
gests that the differences in ER status of the two patient
populations represented by the datasets likely are
caused by the age difference in the two populations
(i.e., the ER populations were not statistically different
from each other; P = 0.11). In addition, our model also
confirms that the age of the patient population has a
very significant influence on the ER status (P < 1×1010).
Cohort of patients with triple negative and highly
proliferative breast cancer
We hypothesized that the western Kenyan cancers
would also be enriched for triple negative breast
A
B
C
Fig. 1 Pathology of Kenyan breast cancer tissue samples. a Experimental design flowchart for this study. Samples were collected, analyzed for
pathology, processed to create a tissue microarray, stained for clinical marker immunohistochemistry, and quantified by statistical analysis. b Pie
chart representations of the distribution of cancer (left) and benign/not cancer (right) pathologies in Kenyan breast tissues analyzed after H&E
staining. Most of these patients were diagnosed with invasive ductal carcinoma (IDC) and mucinous IDC. Most benign samples fell into the category
that includes benign mammary, inflammatory tissue, and fibrocystic disease. (C) H&E staining of representative Kenyan breast cancer samples analyzed
for pathology. Both Patient 1 and Patient 2 have invasive ductal carcinoma (IDC). Patient 2 has significant immune cell infiltration
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cancer (HER2 negative, ER negative, PR negative). We
compared the percentage of patients with triple nega-
tive breast cancer to the percentage of patients in
other breast cancer studies. Indeed, we found a high
representation (33 %) of triple negative breast cancer
in the tissue samples (Table 1).
After determining the receptor status of the malig-
nant samples, we next looked at proliferation in the
non-cancer and cancer samples. Both cancer and
non-cancer TMA tissue samples were stained for the
proliferation marker Ki67 by immunohistochemistry
and quantified for the percentage of Ki67 positive
epithelial cells (Fig. 2b, c). The ER+ or ER- cancer
tissues expressed more Ki67 positive cells than did
the non-cancer samples. The following combinations
were significantly higher in cancer samples compared
to not cancer samples by one-sided t-test: P = 2.834e-05
(ER+ vs. not cancer) and 4.576e-06 (ER- vs. not
cancer), respectively. In addition, both ER+ and ER-
tumors expressed Ki67, with more proliferation in
the ER- tumors than in the ER+ tumors (P = 0.0009
by one-sided t-test to test if ER- is larger than ER+;
P = 0.002 by two-sided t-test to test if ER- is differ-
ent from ER+). Because not only the ER- tumors
but also the ER+ tumors expressed higher Ki67
than did not cancer tissue, this indicates that the
tumors from the Kenyan patients are highly prolif-
erative with a high grade.
Increased infiltration of CD163+ M2 macrophages, CD25+
T regulatory cells, and CD4+ T helper cells, but not CD20+
B cells or CD8+ cytotoxic T cells, in Kenyan breast cancer
tissue
Since the analysis of the pathology of these tumors identi-
fied a large number of tumors with inflammatory cell infil-
tration, we wanted to identify which kinds of inflammatory
cells were recruited to the tumor microenvironment
during breast cancer progression. Macrophages, B cells,
and T cells are among the most common leukocytes found
in the stroma of neoplastic breast tissue [20, 30]. We
stained the patient breast tissue samples for markers used
to distinguish between these inflammatory cell types.
We stained and scored patient tissue samples for CD68
(Fig. 3a, c), which is a macrophage marker, and CD163
(Fig. 3b, c), which stains M2 macrophages. The cancer
tissue samples had increased CD68+ cells as well as in-
creased M2 macrophage activation compared to the
non-cancerous tissues. These results suggest that the
cancer tissues have increased macrophage infiltration,
marked by an increase in M2 macrophages.
To investigate the adaptive immune response in cancer,
we stained and quantified the tissue samples for markers of
both the cellular and humoral immune responses by immu-
nohistochemistry. We stained tissues for CD4 (T helper
cells), CD8 (cytotoxic T cells), and CD20 (B cell marker).
Cancer tissues had increased recruitment of CD4+ T helper
cells (Fig. 4a, d). In contrast, CD20 and CD8 positive cells
Table 2 Comparison of breast cancer studies from East Africa
Study Country City Patients with
Breast Cancer
Retrospective
or prospective
study design
Female Male Ethnic groups
considered in
study
Immune cells
quantified
Median Mean ER+ ER- ER+
(N)# (%) (%) age age (N) (N) (%)
This Study,
Sawe et al.
Kenya Eldoret 48 (68)A Prospective 93 7 Yes CD68, CD163,
CD4, CD8,
CD20, CD25
48.5 51.9 29 20 59
Nalwoga
et al.
Uganda Kampala 65B Retrospective 100 no B No None 49.8 23 42 35
Roy et al. Uganda Kampala 35 (45)B,C Retrospective 96 4 C,B No None 27 18 60
Bird et al. Kenya Kijabe 34 (129)D Prospective 97 3 No None 47 48 29 24
Nyagol et al. Kenya Nairobi 158B Prospective 100 no B No None 47 59 99 37
Wata et al. Kenya Nairobi 54 (219)B,E Retrospective 100 no B No WBC, platelets 45 46.5 30 34 47
Kantelhardt
et al.
Ethiopia Addis
Ababa
352B Retrospective 100 no B No None 40.1-43H 230 122 65
Burson et al. Tanzania Dar es
Salaam
57 (488)I Retrospective 97 3 No None 49.4 33 32 51
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor, TN triple negative (ER-,PR-,HER2-), N number, % = percent, n.d not determined
#The number before the parentheses is the number of patients used for analysis of receptor status and is summarized individually by the indicated superscripts
The number in parentheses represents the total number of patients with breast cancer in the study.
AN = 48 patients with PR and triple negative data. N = 49 with ER, HER2 data. Excluded patients who did not provide consent or who had chemotherapy prior to surgery
BOnly females included in study
CN = 35 patients with triple negative data. N = 44 patients with HER2 data. 2 of 47 (4 %) patients were male but were excluded from the study
DN = 34 patients with HER2/triple negative data. 120 patients with hormone receptor data
EN = 54 patients with HER2 data. N = 64 patients with ER data. N = 64 for PR. Excluded if <18 yrs old, male, or if chart did not have a date of diagnosis
FNo hormonal receptor data in this study
GDefined in this study by staining for Cytokeratin 5/6 and P-Cadherin as basal subtype markers, rather than ER, PR, and HER2
HMean is 43 years old for ER+ and 40.1 years old for ER- patients
IN = 57 patients with ER and PR data. No HER2 data for these patients
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were not differentially recruited to cancer versus non-
cancer tissues (Fig. 4b–d).
Mature CD8+ T cells are cytotoxic effectors of the im-
mune system that support antitumor activity and correl-
ate with improved prognosis in breast cancer patients
[31]. Because the CD8-mediated immune response was
not sufficient to overcome the cancer cells in these
patients, we hypothesized that the tumors developed an
alternative strategy to overcome the cytotoxic activity of
CD8+ T cells. Examples of immunosuppressive strategies
used by tumor cells to escape immune surveillance
include elevated activity of Treg cells to inhibit antitu-
mor immune response, upregulation of CTLA-4 and
PD-L1; TGF-ß production; and loss of T cell antigen
presentation in the tumor (reviewed in [32]).
We examined the infiltration of CD25+ regulatory
T cells (Tregs) into the tumor. A primary function of
CD25+ Tregs is to inhibit the antitumor activity of
CD8+ cytotoxic T cells [31]. Also, M2 macrophages,
which are increased in these tumors (Fig. 3), can re-
cruit Tregs [33]. We looked at the recruitment of
Tregs by immunostaining the tissue samples for
CD25. Interestingly, we saw an increase in the num-
ber of CD25+ cells recruited to the cancer compared
to the non-cancer tissues (Fig. 5a, b). These data suggest
that CD25+ Tregs are recruited to breast malignancies in
a subset of the western Kenyan patient cohort and may
impair their immune response to tumors in these patients.
Discussion
In this prospective study, we characterized breast can-
cer tissue samples collected from consecutive patients
of western Kenya. We found that a high percentage of
these patients were diagnosed with cancer at a young
age and developed a low three-year survival rate. The
majority (59 %) of the breast tumors expressed estro-
gen receptor, while 33 % of the tumors were triple
negative. The breast tumors were highly proliferative
and high grade invasive ductal carcinomas with im-
mune cell infiltration. The immune cells recruited to
the tumor included cells expressing markers CD68,
CD163, CD4, and CD25. Because a western Kenyan
breast cancer patient population has not been studied
previously, this study has important implications for
identifying appropriate treatment strategies that are re-
quired to reduce mortality of Kenyan breast cancer
patients, who currently have limited diagnostic and
treatment opportunities.
Estrogen receptor status
Though the majority of the breast tumors from our
patient cohort were ER+, roughly 33 % of the breast
cancer patients in our study had triple negative breast
tumors, which also are indicative of poor prognosis.
These results are consistent with other studies that find
that 23 %-44 % of breast cancer tissue samples col-
lected from East African women in Kenya, Ethiopia,
and Uganda are triple negative [17, 19, 25–27, 34].
African women with breast cancer also have a higher
prevalence of ER- and triple negative cancer compared
with Caucasian populations [6, 14, 19, 34, 35]. These
results also are similar to that seen in breast tumors
from black women in the U.S. and in the United
Kingdom, as compared to white women, where the
patient cohorts also had a high representation of triple
negative/basal subtype breast tumors [36, 37].
Treatment of breast cancer in Western Kenya
Testing for ER status is not a standard test for breast
cancer treatment in Kenya but would provide a signifi-
cant advancement in directing the treatment strategy
of these patients. When markers have been used to
direct chemotherapy and hormone therapies as treat-
ment strategies, the patients have had improved
Table 2 Comparison of breast cancer studies from East Africa (Continued)
Study ER- PR+ PR- PR+ PR- HER2+ HER2- HER2+ HER2- TN TN Time Period of
Sample Collection
Date of
Publication(%) (N) (N) (%) (%) (N) (N) (%) (%) (N) (%)
This Study,
Sawe et al.
41 19 29 40 60 7 42 14 86 16 33 2011–2013
Nalwoga
et al.
65 15 50 23 77 19 46 29 71 34 G 1993–2002 2007
Roy et al. 40 5 39 11 89 16 36 2000–2004 2011
Bird et al. 9 25 26 74 15 44 2001–2007 2008
Nyagol et al. 63 77 81 49 51 44 114 28 72 44 28 2002–2004 2006
Wata et al. 53 28 36 44 56 19 35 35 65 2007–2008 2013
Kantelhardt
et al.
35 176 168 51 49 n.d. n.d. n.d. n.d. 2005–2010 2014
Burson et al. 49 29 36 45 55 n.d. n.d. n.d. n.d. 2009–2010 2010
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survival and reduced metastasis rates [28]. Unfortu-
nately, because of limited resources in Kenya, clinical
marker testing and treatments for these patients are
particularly challenging [1, 6].
Since the majority of the tumors in this study were ER+,
this suggests that the majority of these western Kenyan
patients are candidates for treatment with hormone ther-
apy, such as tamoxifen, fulvestrant, or aromatase inhibitors.
In contrast, since almost all ER-tumors were triple negative,
the patients with ER-tumors instead should be treated with
chemotherapy and/or radiation. However, the lack of facil-
ities for chemotherapy and radiation make it imperative
that efforts should be focused on early detection by
community education and screening. For example, Moi
Teaching and Referral Hospital in Eldoret, Kenya, where
this study was initiated, has standard of care for breast
A
B
C
Fig. 2 Heterogeneous expression of ER, PR, and HER2 receptors and increased proliferation. a Representative tissue samples from cancer and not
cancer tissues that were stained for HER2, ER, and PR receptor expression. Examples of tissue that stained positively and negatively for the receptors are
included. b Representative cancer and not cancer samples stained for the Ki67 proliferation marker. c Data plot analysis of Ki67 positive cells in ER+ vs.
ER- tissue samples. Ki67 staining is significantly different between tissues from not cancer, ER+, and ER- breast samples (P < 0.0001, ANOVA) in ER- tissue
samples, indicating high grade and an increase in cellular proliferation. The following combinations were significantly different by one-sided
t-test: P = 2.834e-05 (ER+ vs. not cancer), 4.576e-06 (ER- vs. not cancer), and P = 0.0009 (ER- vs. ER+). The bar represents the median of all
samples in the indicated cohort and includes any unstained samples
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cancer patients that predominantly includes surgical proce-
dures/mastectomy and chemotherapy (personal observa-
tion). Because this hospital currently does not have a
radiotherapy machine, radiotherapy is not even an
option for these patients without additional resources
and significant travel [38].
Ethnic groups and regional differences in Western Kenya
Our study uniquely includes ethnic group information
on its patient population. The breast cancer patients in
this study have a different genetic background from
population in other regions throughout Kenya based on
the ethnic population data. The Uasin Gishu County
website suggests that this county is “largely a cosmopol-
itan region, with the Nandi people of indigenous
Kalenjin communities having the highest settlement.”
Similar to the county data, the patients from MTRH in
our study are predominantly in two ethnic groups:
Luyha (38 %) and Kalenjin (34 %). In contrast, nationally
the Kikuyu ethnic group is ranked first (22 %), followed
by Luhya (14 %), and Kalenjin (12 %). No ethnic group
data were included in the other breast cancer studies in-
cluding patients from East Africa. However, the Nairobi
ethnic group demographics differ from Eldoret ethnic
group demographics and likely are reflected in their pa-
tient populations.
A
C
B
Fig. 3 Kenyan breast cancer tissue samples have increased macrophage infiltration in primary breast tumors. a Data plot analysis of IHC analysis
for the macrophage lineage utilizing a CD68 antibody. Quantitative analysis of the staining indicates a significant increase in percent of CD68+
stained area (P< 0.0001; Mann-Whitney). b Data plot of IHC analysis for the M2 macrophage lineage utilizing a CD163 antibody. Quantitative analysis of
the IHC staining revealed a significant increase in percent of CD163 stained area (P ≤ 0.0001; Mann-Whitney) in M2 macrophages in cancerous Kenyan
breast tissues versus noncancerous Kenyan breast tissues. c Immunohistochemistry of representative noncancer and cancer samples for both general
macrophage lineage (CD68) and the M2 macrophage lineage (CD163). Because the graphs are a log scale, any samples with unstained sections
(i.e., zero) are not included in the graph. The bar represents the median of all samples in the indicated cohort and includes any unstained samples
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Male breast cancer
We uniquely included men who developed breast cancer
in the analysis of our study and found a rate of 7 % male
breast cancer. This rate of male breast cancer is very
high and is unusual. While most of the studies on East
Africa patients excluded male patients from their ana-
lysis [17, 25–28], three other East Africa studies reported
a high rate of male breast cancer (3–4 %) but have a lower
rate compared to our study [19, 26, 29]. The percentage of
male breast cancer patients was significantly different from
other large breast cancer population studies from Tunisia,
Nigeria, and the United States (Additional file 2: Table S2).
This suggests that the high percentage of male patients in
Eldoret patients is unlikely due to chance alone.
Immune cell infiltration
To our knowledge, before this study, immune cell dis-
tribution by immunohistochemistry has not been stud-
ied in any other patient cohorts from Africa, making
this study significant. Infiltration of macrophages, B
cells, and T cells often increases with and are required
for pathological breast cancer progression (reviewed in
[20, 31, 39, 40]). Infiltration of mouse breast tumors
with macrophages leads to an increase in breast cancer
progression and lung metastasis, while depleting mac-
rophages reduces them [40]. In addition, transgenic
mouse models of breast cancer that are deficient in
CD4+ cells initially developed primary tumors at simi-
lar rates but developed lung metastasis at a lower
A B C
D
Fig. 4 Distribution of CD4+, CD8+, and CD20+ cells in Kenyan breast cancer tissue samples. a Data analysis comparing the not cancer and cancer
samples stained for T helper cell presence using a CD4 antibody. Significant increase was seen in T helper cell infiltration in the cancer samples
shown by a higher percentage of CD4+ stained cell area (P = 0.03; Mann-Whitney). b Data analysis comparing noncancerous and cancerous
samples stained for CD8+ cytotoxic T cells. No significant difference was seen in cytotoxic T cell infiltration in the cancerous samples, as shown by
percentage of positively stained cell area (n.s.; Mann-Whitney). c Data analysis comparing the noncancerous to the cancerous samples stained for
CD20+ B cells. No significant difference was seen in CD20+ cell infiltration in the cancerous samples, as shown by percentage of CD20+ stained cell
area (n.s.; Mann-Whitney). d Immunohistochemistry of CD4, CD8, and CD20 in representative cancer and not cancer tissue samples.Because the
graphs are log scale, any samples with unstained sections (i.e., zero) are not included in the graph. The bar represents the median of all samples in the
indicated cohort and includes any unstained samples
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frequency than wildtype mice, suggesting that CD4 + T
cells are required for breast cancer during lung metastasis
[20]. These leukocytes also contribute to therapeutic re-
sponse. Interestingly, cytotoxic drugs themselves can
trigger tumor cells to release macrophage/monocyte
recruitment factors, which in turn promote the infiltra-
tion of tumor-associated macrophages to the tumor
cells. In addition, when macrophage recruitment is
blocked with antagonists to colony stimulating factor 1
receptor (CSF1R) and in combination with paclitaxel,
this treatment causes both an increase in primary
breast tumor and lung metastasis as well as increased
tumor suppression that was CD8+ CTL cytotoxic T
cell-dependent [39].
A
B
C
Fig. 5 Increased infiltration of regulatory T cells in Kenyan breast cancer tissue. a Data analysis comparing the noncancerous and cancerous
samples stained for CD25+ regulatory T cells. A significant increase was seen in regulatory T cell infiltration in the cancer samples, as shown
by a higher percentage of positively stained cells (P = 0.03; Mann-Whitney), increased number of positively stained cells per area (P = 0.01;
Mann-Whitney), and a higher percentage of CD25 stain per area (P = 0.0001; Mann-Whitney). Because the graph is a log scale, any samples
with unstained sections (i.e., zero) are not included in the graph. The bar represents the median of all samples in the indicated cohort and
includes any unstained samples. b Representative cancer and not cancer tissue samples stained for CD25. c Proposed T cell mechanism of
action in Kenyan breast cancer model. (Top) Without a strong presence of regulatory T cells (e.g., benign Kenyan tissue), cytotoxic and T helper cells
are able to combat and suppress the cancer cell, leading to increased apoptosis and loss of proliferation. (Bottom) When T regulatory cells are present
(e.g., Kenyan breast cancer tissue), they block cytotoxic and helper T cells from fighting off the cancer cells
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In our study, the breast cancer tissue samples tested had
increased T cell and macrophage immune cell marker
(CD4, CD25, CD63, CD163) expression compared to
benign tissue. M2 macrophages (CD163+) and regulatory
T cells (CD25+) in particular are associated with pro-
tumor roles during breast cancer progression. In fact, M2
macrophages and Tregs have a complimentary and syner-
gistic relationship to promote their plasticity [41]. Tregs
can differentiate monocytes/macrophages into CD163+
M2 macrophages [42]. M2 macrophages also can secrete
chemokines that promote the induction, differentiation,
and recruitment of Tregs [33].
In normal tissues, Tregs prevent autoimmune responses;
in tumors, Tregs prevent the destruction of tumors by
CD8+ cytotoxic T cells and contribute to cancer cells evad-
ing their detection by the immune system (Fig. 5c) [31].
Moreover, infiltration of Tregs into breast tumors is prog-
nostic of reduced survival in patients [21]. Conversely,
therapeutic strategies that eliminate the Tregs to modulate
Treg activity (e.g., anti-CD25 mAb and CTLA-4 antago-
nists) have had some success in treating melanoma
patients [43]. The Kenyan cancer patients with tumors that
express high CD25+ cells might benefit from a similar
therapeutic strategy designed to overcome the inhibitory
immune response and to improve the anti-tumor immune
response for patients with high levels of Tregs within the
tumor site. Future research will be required to determine if
immune modulators that eliminate Tregs or increase
tumor destruction by CD8+ T cells will help in overcoming
the aggressive breast cancer seen in Kenya.
Patient population of this study
With our current sample size, our study identified both
clinical features (e.g., male breast cancer, young age at
presentation, estrogen receptor status) and immune cell
features of this patient population that are worthy of
additional studies. Our breast cancer patient sample size
that was used for hormone receptor status (N = 48 breast
cancer tissue with known hormone receptor status of
breast cancer of 68 total patients) is comparable to other
breast cancer studies from Kenya, Uganda, and Tanzania:
(N = 34 with hormone receptor status of 129 total pa-
tients; [19]); (N = 54 with hormone receptor status of 219
total patients; [28]); (N = 158; [27]); (N = 35 patients with
hormone receptor status of 45 total patients enrolled in
study; [26]); (N = 65; [25]); and (N = 57 with hormone
receptor status of 488 total patients; [29]). In fact, a large
meta-analysis of African breast cancer studies that in-
cluded receptor status did not find a small study bias that
affected the receptor status in the studies analyzed from
sub-Saharan Africa, which includes Kenya [44].
Of the studies mentioned above, only two were
prospective studies [19, 27]. Older retrospective samples
trended to have a lower percentage of ER+ tumors
compared to prospective studies [44]. In a meta-analysis
of studies from Sub-Sahara Africa, tumor tissue samples
from retrospective studies included 10 % less ER+ tumors
compared to prospective studies, suggesting increased bias
in retrospective studies [44]. Our study was strength-
ened by being a prospective study and by not being a
convenience sample.
Changing landscape of breast cancer in Africa
Between 1980–2010, breast cancer incidence and death
increased in Kenya and throughout Africa [2]. The cause
of this increase in breast cancer is unknown but is spec-
ulated to be associated with risk factors, such as obesity,
the increased awareness and detection of breast cancer,
and the aging population [2, 3, 6]. However, an environ-
mental factor that contributes to the aggressive nature
of the disease progression would also be consistent with
the results of our study, which include the young age at
the presentation of the disease, the high percentage of
males with breast cancer, and the suppressed antitumor
immune response.
Interestingly, in contrast to our study, the prevalence
of ER-negative breast cancer in East African-born blacks
who immigrate to the U.S. is similar to the prevalence
seen in U.S.-born whites [23]. However, the study’s East
African-born population primarily was born in Ethiopia
or Eritrea and may not represent the western Kenya
patient population in our study. In contrast to this East
African-born population, the ER-negative breast cancer
in West African-born blacks is similar to the prevalence
in U.S.-born black women. This finding suggests differ-
ences in the disease progression between black popula-
tions born in West or East Africa. Because these
differences are not apparent when populations remain in
Africa, the differences in prevalence are likely to be
caused by a combination of environmental and genetic
factors. Because of the small number of patients who
donated detailed clinical data, our study is inconclusive
to determine if these factors impact or affect the risk of
breast cancer in Kenyan breast cancer. In future studies,
we will track these patients over time to define more
clearly which patients have the worst prognosis. Such
studies will be important to identify the mortality rate of
the patients, since many countries, including those in
sub-Saharan Africa, do not have complete mortality data
and instead must estimate mortality rates [2].
Conclusions
Our data suggest that the breast cancer developing in
patients of western Kenya is aggressive and is associated
with diagnosis at a young age, high proliferative index and
high immune cell infiltration in the primary tumors, and
poor three-year patient survival. Our characterization of
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this patient population using clinical markers suggests pos-
sible treatment strategies that will be effective in improving
the outcome for these patients. This research enhances our
ability to diagnose and treat breast cancer patients in
Kenya. In addition, achievements in our understanding of
the etiology and treatment of a unique population of
Kenyan patients with aggressive breast cancer may help
identify and treat other poor prognostic breast cancers from
other populations with a similar cancer disease progression.
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